HZ-R078
/ HealZen Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
HZ-R078: A tumor-enriched STAT3 degrader for treating T-cell lymphoma in pre-clinical models
(AACR 2023)
- "HZ-R078 is a selective and potent STAT3 degrader which has tumor-enriched distribution character. The pre-clinical efficacy and safety study support its further development in clinical stage for T-cell lymphoma therapy."
Preclinical • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • STAT1 • STAT2 • STAT3 • STAT4 • STAT5 • STAT5B • STAT6
1 to 1
Of
1
Go to page
1